Senior Project Manager

Thermo Fisher launches LabLink 360 QA software. June 26, 2026 - Thermo Fisher Scientific has launched the Thermo Scientific LabLink 360 Quality Assurance software, designed to help clinical laboratories simplify quality control workflows, accelerate QC review and decision-making, improve visibility into QC performance, and manage QC operations. The software consolidates QC data, automates routine review steps, and surfaces actionable insights through data visualizations and a centralized dashboard that brings all QC metrics into a single, actionable view. Built-in peer group benchmarking enables real-time comparison directly within daily QC workflows, while affiliated lab management provides unified oversight across multisite and referral networks. The software complements the Thermo Scientific MAS Quality Controls portfolio and integrates with MAS Max Load and Go automation workflows for high-volume and automated testing environments.

2026 DIA Global Annual Meeting: what drives sponsors to mixed outsourcing models and what the transition looks like. In this video interview from the 2026 DIA Global Annual Meeting, Nick Scott of Biogen and Samantha Hadfield of Thermo Fisher Scientific, explain why mixed FSP models are becoming a strategic tool for sponsors seeking greater agility and how geography and portfolio structure shape the decision. Full interview summary. In a recent video interview with Applied Clinical Trials at the 2026 DIA Global Annual Meeting, Nick Scott, head of strategic resourcing and performance optimization at Biogen, and Samantha Hadfield, vice president of operational delivery at PPD FSP Solutions, Thermo Fisher Scientific, discussed the drivers and dynamics of mixed outsourcing models in clinical operations, following a session moderated by ACT Senior Editor Andy Studna. Scott opened by framing Biogen's move to a mixed FSP model as part of a broader strategic journey to accelerate drug development and allocate resources more deliberately - retaining core competencies in-house while leveraging external partners in areas where building that capability internally does not make strategic sense. Hadfield added a geographic dimension to that framing, describing how large pharma companies often use FSP FTEs to maintain dedicated presence in core countries while relying on unitized FSO arrangements to provide flexibility in markets with lower clinical activity. On the question of where mixed models create the most meaningful gains, both speakers pointed to portfolio dynamics as the primary driver. For Hadfield, the value is most evident when a sponsor's portfolio diversifies or expands - whether through organic growth or M&A - and the ability to bring in the right therapeutic expertise at the right time without growing internal infrastructure becomes a competitive advantage. Scott framed it around volume thresholds, noting that a full FSP model becomes more viable as volume grows, while the mixed approach provides a practical and efficient solution during the earlier or lower-volume phases of a sponsor's development program. The conversation closed on the importance of partnership fundamentals - communication, expectation alignment, shared accountability, and cultural understanding. Both speakers emphasized that the success of any mixed model comes down not just to the model itself but to the deliberateness of the journey: a clear vision of the end state, a well-documented implementation plan, and the kind of trust that allows both sides to solve problems together rather than deflect blame.

PUXANO presents Tilted Graphene Grids at the Cambridge CryoEM Consortium. 11 june 2026. PUXANO attended the Cambridge CryoEM Consortium Biannual Meeting in Cambridge, UK, organized by Thermo Fisher Scientific. The meeting brings together leading cryoEM experts from academia and industry, including representatives from GSK, AstraZeneca, Nxera, UCB Pharma, Astex, the MRC Laboratory of Molecular Biology (LMB), and the University of Cambridge. Earlier this month, PUXANO attended the Cambridge CryoEM Consortium Biannual Meeting in Cambridge, UK, organized by Thermo Fisher Scientific. The meeting brings together leading cryoEM experts from academia and industry, including representatives from GSK, AstraZeneca, Nxera, UCB Pharma, Astex, the MRC Laboratory of Molecular Biology (LMB), and the University of Cambridge. PUXANO was invited to present its recent developments in sample support technologies, with a particular focus on its Tilted Graphene Grids. The invitation reflected growing interest in new approaches for tackling challenging cryoEM samples and improving data collection outcomes. During the meeting, its CEO, Wouter Van Putte, shared the latest results from its work on graphene-coated and tilted grids. These technologies are designed to help overcome common challenges in cryoEM sample preparation and data acquisition, making them particularly relevant for difficult biological specimens. The event provided an excellent opportunity to exchange ideas with researchers and industry scientists working at the forefront of structural biology. Beyond presenting its own work, Puxano greatly appreciated the high-quality talks covering the latest advances in cryoEM technologies, methodologies, and workflows. Meetings like the Cambridge CryoEM Consortium are valuable opportunities to gather feedback from experienced users, discuss emerging challenges in the field, and explore future collaborations. Puxano is grateful to the organizers, and in particular Pablo Castro Hartmann, for the invitation and for hosting such a well-structured and insightful event. Puxano look forward to continuing these discussions and further advancing cryoEM sample support technologies for the structural biology community.